• Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says
  • Transgene Completes Enrollment for Phase 2 Trial of Triple Combo NSCLC Therapy
  • FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule
  • Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma
  • Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors
  • Cancer Vaccine VBI-1901 Well-Tolerated in Recurrent Glioblastoma Patients, Early Phase 1/2a Data Show
  • Imfinzi Combo Therapy Extends Survival of Advanced SCLC Patients, Phase 3 Trial Shows
  • DPX-Survivac-Keytruda Trio Shows Promise in DLBCL Patients
  • Complete Remission Induced in B-cell ALL Patients After Single Dose of FasT CAR-19 Therapy, Preliminary Data Show
  • Tislelizumab Produces Promising Anti-Cancer Activity in Advanced Nasopharyngeal Cancer Patients, Preliminary Data Show
  • Keytruda Found to be Safe as Cancer Treatment for HIV Patients, Phase 1 Trial Shows
  • Bemcentinib-Keytruda Combo Provides Durable Response in Advanced NSCLC, Phase 2 Trial Shows